1 February 2023 - Medexus Pharmaceuticals wishes to inform investors that the company has reached an agreement with the provincial government of Quebec for government sponsored coverage of Cuvposa (glycopyrrolate 1 mg/5 mL oral solution).
Cuvposa will be listed for public reimbursement on the Public Prescription Drug Insurance Plan of the Régime de l’Assurance Maladie du Québec, or RAMQ, starting 1 February 2023.